The FDA on January 10, 2014 approved the use of MEKINISTĀ® in combination with TAFINLARĀ® for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, as detected by an FDA-approved test. Both MEKINISTĀ® and TAFINLARĀ® are products of GlaxoSmithKline, LLC.
Other Pages – Bottom Ad
Advertisement
Subscribe
